This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes estimated from the literature were: 
Study designs and other criteria for inclusion in the review
The authors stated that the literature was reviewed for all clinical estimates. When DS-specific data were not available, clinical estimates were derived from the general population using conservative estimates (thus biasing the analysis in favour of screening). Details of the primary studies (study samples, patient demographics and study design) were not reported. The utility weights for treated CD were obtained from a published study in which the SF-36 short form was used in Scandinavian patients. The utility of lymphoma was obtained from a Dutch study.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Twenty-two primary studies provided the clinical inputs.
Methods of combining primary studies
When a range of clinical values was available for a single estimate, the median value was chosen. In some circumstances the analysis was biased in favour of the screening strategy.
The effectiveness of a GFD in preventing lymphoma was 62% (range: 51 to 100). This meant that the adherence to a GFD was estimated to be 62% and that adherence to a GFD decreased the risk of lymphoma to that of the general population.
The life expectancy in DS was 56 years (range: 52 to 60).
The life expectancy for persons with DS who develop lymphoma was 48 years (range: 38 to 58).
The prevalence of CD in asymptomatic children with DS was 3.3% (range: 1 to 6.5).
The risk of lymphoma was 0.02% (range: 0.01 to 0.047).
The relative risk of lymphoma in CD with respect to the general population was 6.3.
The sensitivity of serologic tests was 95.7% (range: 90.3 to 98.1) and the specificity was 99% (range: 94.6 to 99.8).
The utility associated with a GFD was 0.99 (range: 0.99 to 1.00).
The utility associated with lymphoma was 0.70 (range: 0.60 to 0.81).
Measure of benefits used in the economic analysis
Three summary benefit measures were used in the economic analysis. These were the quality-adjusted life-years (QALYs), the life-years (LYs) and the probability of preventing one case of lymphoma. All measures were calculated using a modelling approach. There was little information on the sources of the utility values. Discounting does not appear to have been performed, although it might have been relevant given the long time horizon of the analysis.
Direct costs
The analysis of the costs was restricted to the direct medical costs associated with screening, endoscopy and small bowel biopsy, GFD and the treatment of lymphoma. Transportation costs were not considered in order to bias the analysis in favour of screening. The costs of complications arising from endoscopy or small bowel biopsy were not included because these events are very rare. The unit costs were presented for some items but the resource quantities were not reported. The costs were derived from several sources such as Medicare or Medicaid claims, published studies and the authors' institution. The sources of the quantities of resources used were not provided. The price year was not reported. Discounting does not appear to have been performed, although it might have been relevant given the long time horizon of the analysis.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered.
Currency

US dollars ($).
Sensitivity analysis
One-and two-way sensitivity analyses were carried out to assess the robustness of the cost-effectiveness and cost-utility ratios to variations in key clinical and economic inputs. Ranges of values were based on published data. A threshold analysis, which considered a willingness-to-pay level of $50,000 per QALY, was also performed.
Validity of estimate of measure of benefit
All benefit measures were appropriate as the study aimed to assess the impact of the screening strategies on relevant dimensions of health such as (quality-adjusted) survival and cases of CD-related complications. Quality of life, in particular, represents a key aspect of the patients' health. The utility estimates taken from published studies of Scandinavian and Dutch patients were reported. It was unclear whether these estimates are transferable to the US context, although the authors carried out sensitivity analyses to deal with this issue. Discounting was not reported although US guidelines recommend the calculation of the present value of future benefits.
Validity of estimate of costs
The perspective of the economic analysis did not reflect the viewpoint of society since, as the authors stated, productivity losses and transportation costs were not considered. It was noted that the exclusion of these costs should have favoured the screening strategy. The authors clearly explained the estimation of the costs and provided details on the selection of cost estimates from the available sources. When the costs were derived from other countries and from different periods, appropriate currency conversions were carried out and the effect of inflation was considered. Owing to the variability across sites, extensive sensitivity analyses were carried out on the cost estimates. Discounting was not performed, although it was relevant given the long time horizon of the model. The price year was not reported, which could hinder any reflation exercises in other time periods.
